Strauss-Elite to move to Petah Tikva

Strauss-Elite will move its main offices to Petah Tikva from Ramat Gan, the company said.

By DANIEL KENNEMER
September 19, 2006 08:52

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Strauss-Elite will move its main offices to Petah Tikva from Ramat Gan, the company said. In Petah Tikva, the Strauss-Elite group has rented a 10-floor, 10,500 square-meter building in the Park Yannai complex on Rehov Hasibbim for $150,000 a month. The company plans to move to the site before the end of 2007, and may continue the current rental contract for up to 25 years. Strauss-Elite recently sold its original Bauhaus-period headquarters in central Ramat Gan to Donald Trump and Crescent Heights - who plan to develop a 70-floor, $44 million residential tower on the site.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS